Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT01767766 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT01767766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01767766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 7, 2013
Completion date
February 28, 2018
Enrollment
90 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, hodgkin's lymphoma, non-hodgkin's lymphoma, peripheral t-cell lymphoma